2012 HIV drug pipeline

New HIV Drugs in the Pipeline – 2012

Gilead has completed and released 48-week data from ongoing phase 3 studies of a four-drug fixed dose combination (elvitegravir, cobicistat, tenofovir, and FTC- called QUAD), as it has with studies of the integrase inhibitor elvitegravir and the pharmacokinetic booster cobicistat.  QUAD  will likely be approved for treatment naive patients after August this year.  Results from …

New HIV Drugs in the Pipeline – 2012 Read More »